Merus N.V.
http://www.merus.nl
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Merus N.V.
Merus Gains Momentum Ahead Of Keytruda Combination Results
Results in head and neck cancer for its lead bispecific antibody are expected at ASCO, with signs the FDA could accept an accelerated approval application based only on overall response rate data.
Gilead’s Trispecific Alliance With Merus Continues Its Push In Novel Cancer Tech
Deal Snapshot: Gilead adds to its pipeline of multispecific antibodies for cancer, while Merus gets a first partner for its trispecific platform.
Under LG Chem’s Wing, AVEO Oncology Steps On R&D Gas Pedal
With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.
US FDA’s Breakthrough Designation Pace Slows, But Topics Broaden
The 19 breakthrough therapy designations awarded so far this year run the gamut from areas that traditionally have not fared well with BTDs, like cardiovascular and respiratory disease, alongside the traditional cancer and orphan disease tentpoles.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Merus B.V.
- Merus BV
- Merus NV
- Merus US, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice